Aurum Ventures MKI
VC Fund
Ramat Gan, Israel
Aurum Ventures MKI is a VC fund in Ramat Gan focused on Biotechnology and Medical Device. Aurum Ventures MKI provides value added growth capital to exceptional entrepreneurs within the fields of life-sciences and clean-tech. While we focus on investing in unique, cutting edge technologies that will mature into successful business companies, our investments reflect our own values, so we prefer investing in companies that, through theirsound commercial propositions, also contribute to the well-being of mankind. Our team is comprised of senior and experienced hands-on executives who work actively with the portfolio companies in enhancing their strategic and execution capabilities. We typically take a long-term approach, understanding that ventures in the life sciences and clean tech take time to mature and be successful.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Aurum Ventures MKI invests in
Stages Aurum Ventures MKI invests in
Countries Aurum Ventures MKI invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical Device 3 (50%)
- Information Technology 3 (50%)
- Manufacturing 2 (33%)
- Water 1 (17%)
Stage
- Seed 1 (17%)
- Series A 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan J. Gelvan
Managing Director Life Science
|
Managing Director Life Science | Total investments: 0 | Find email | |
|
Morris Kahn
Principal investor
|
Principal investor | Total investments: 0 | Find email | |
Nili Lesnik
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scopio Labs
|
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods. | $50M / Series C / Feb 09, 2022 | |
|
Scopio Labs
|
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods. | $50M / Series C / Feb 09, 2022 | |
KidneyCure
|
KidneyCure Ltd. is developing proprietary cell therapies aiming to prevent progression of Chronic Kidney Disease. The scientific basis and motivation for KidneyCure’s approach was provided by a world-renowned authority in Nephrology Prof. Benjamin Dekel, through genuinely pioneering research carried in his laboratory at Sheba Medical Center inIsrael, one of the world’s leading medical centers. KidneyCure’s unique 3D renal cell cluster technology is expected to significantly delay the need for dialysis and transplantation and give millions of patients an opportunity to live longer higher quality lives. | $4M / Nov 18, 2018 | |
Nucleix
|
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called LungEpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel. | $3M / Seed / May 24, 2016 | |
LifeBond
|
LifeBond is a leader in the development and manufacturing of bio-surgical medical devices for tissue repair that are intended to improve the recovery of patients and to create an environment that supports the body’s natural healing process and promotes tissue repair. Of natural origin, elastic, adhesive, durable and yet absorbable, the company’sdevices can be used to fill a long list of unmet surgical needs. LifeBond’s first product, LifeSeal™, is designed to provide staple-line reinforcement in bariatric and colorectal operations. It was recently studied in an international pilot clinical study in Europe. The company’s second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development. Other pipeline products include tissue adhesives and absorbable hemostats. LifeSeal™, LifeMesh™ and other LifeBond™ products are investigational and have not yet been approved for sale in the US or in any other market. For more information please visit use at: www.life-bond.com | $27M / Series D / Aug 05, 2015 | |
BPT
|
BPT is developing and commercializing advanced membranes-based separation solutions addressing the unique needs of the water and wastewater treatment for key industrial processes. BPT patented chemically-stable membrane technology enable customers in the landfill, mining, chemical, biopharma and food industries to comply with the environmentalregulations, reuse water and reduce production costs. BPT membranes are field proven to enable lowest cost reclamation of some of the most aggressive and vexing industrial waste water streams. | $2.5M / Series A / Apr 19, 2007 |
Co-Investors
Ilex Medical
2 deals together
LR Group
2 deals together
Mivtach Shamir Holdings LTD
2 deals together
OTV
2 deals together
OurCrowd
2 deals together
Mizrahi Tefahot Bank
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Aurum Ventures MKI invest in?
Aurum Ventures MKI invests primarily in Biotechnology, Medical Device and Information Technology startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aurum Ventures MKI?
Public channels for Aurum Ventures MKI include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aurum Ventures MKI?
The team at Aurum Ventures MKI includes Dan J. Gelvan (Managing Director Life Science), Morris Kahn (Principal investor) and Nili Lesnik (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
